Immunotherapy for advanced melanoma

Lei Fang, Anke S. Lonsdorf, Samuel T Hwang

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen has resulted in objective response rates approaching 50%. For a number of reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain challenging and potentially life-threatening issues.

Original languageEnglish (US)
Pages (from-to)2596-2605
Number of pages10
JournalJournal of Investigative Dermatology
Volume128
Issue number11
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

T-cells
Adoptive Transfer
Immune system
Immunotherapy
Interleukin-2
Melanoma
Immunity
Cell- and Tissue-Based Therapy
Autoimmunity
Immune System
Vaccination
Maintenance
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Immunotherapy for advanced melanoma. / Fang, Lei; Lonsdorf, Anke S.; Hwang, Samuel T.

In: Journal of Investigative Dermatology, Vol. 128, No. 11, 11.2008, p. 2596-2605.

Research output: Contribution to journalReview article

Fang, Lei ; Lonsdorf, Anke S. ; Hwang, Samuel T. / Immunotherapy for advanced melanoma. In: Journal of Investigative Dermatology. 2008 ; Vol. 128, No. 11. pp. 2596-2605.
@article{d2aabf7ca2fb4ea0b9d2e7ff1618f72e,
title = "Immunotherapy for advanced melanoma",
abstract = "Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen has resulted in objective response rates approaching 50{\%}. For a number of reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain challenging and potentially life-threatening issues.",
author = "Lei Fang and Lonsdorf, {Anke S.} and Hwang, {Samuel T}",
year = "2008",
month = "11",
doi = "10.1038/jid.2008.101",
language = "English (US)",
volume = "128",
pages = "2596--2605",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Immunotherapy for advanced melanoma

AU - Fang, Lei

AU - Lonsdorf, Anke S.

AU - Hwang, Samuel T

PY - 2008/11

Y1 - 2008/11

N2 - Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen has resulted in objective response rates approaching 50%. For a number of reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain challenging and potentially life-threatening issues.

AB - Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen has resulted in objective response rates approaching 50%. For a number of reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain challenging and potentially life-threatening issues.

UR - http://www.scopus.com/inward/record.url?scp=53949108366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53949108366&partnerID=8YFLogxK

U2 - 10.1038/jid.2008.101

DO - 10.1038/jid.2008.101

M3 - Review article

C2 - 18927541

AN - SCOPUS:53949108366

VL - 128

SP - 2596

EP - 2605

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 11

ER -